Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GPC Biotech cancer news

GPC will restructure and reduce its headcount by 46 (15%) to 270. The move affects GPC's U.S. staff, with cuts in the company's commercialization, R&D

Read the full 252 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE